Astrazeneca ADR Aktie
64,50 €
Deine Einschätzung
Astrazeneca ADR Aktie
Was spricht für und gegen Astrazeneca ADR in den nächsten Jahren?
Pro
Kontra
Rendite von Astrazeneca ADR im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Astrazeneca ADR | 0,00 % | -0,77 % | 5,74 % | -5,84 % | 4,88 % | 52,12 % | - |
GSK plc ADR | -0,54 % | -3,14 % | -4,64 % | 10,12 % | 10,12 % | -6,33 % | -16,38 % |
Bayer AG ADR | 3,88 % | -5,63 % | 5,51 % | -55,92 % | -22,09 % | -50,00 % | -55,63 % |
Roche Holding AG ADR | 0,23 % | -2,17 % | -4,63 % | -20,08 % | -12,72 % | -19,70 % | - |
Kommentare
https://www.nasdaq.com/articles/is-it-too-late-to-buy-the-most-promising-pipeline-in-the-pharma-industry-2021-05-28
News
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.
Weight-loss drugs are hot. Just look at the recent performances of Eli Lilly (NYSE: LLY), which won U.S. approval in November for Zepbound, and Novo Nordisk (NYSE: NVO), which markets Ozempic and
AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript
AstraZeneca Plc (NASDAQ: AZN)Q4 2023 Earnings CallFeb 08, 2024, 6:45 a.m. ET
Andy Barnett
Source Fool.com
AstraZeneca: Rebound in 2024 with double-digit earnings growth
U.K.-based AstraZeneca PLC (NASDAQ: AZN) is up 8.95% in the past month as investors grow optimistic about the company's improved earnings outlook for 2024. Not only are sales of cancer and